Exactus, Inc. (EXDI) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Exactus, Inc. (EXDI) ein Healthcare-Unternehmen mit einer Bewertung von 0.
Zuletzt analysiert: 17. März 2026Exactus, Inc. (EXDI) Gesundheitswesen & Pipeline-Uebersicht
Exactus, Inc., a subsidiary of Ceed2Med, LLC, focuses on the production and supply of hemp-derived ingredients and feminized hemp genetics. Targeting the cosmetic, wellness, and pharmaceutical industries, the company offers specialty cannabinoid products and white-label services, positioning itself within the burgeoning hemp market amidst evolving regulations and increasing competition.
Investmentthese
Exactus, Inc. presents a high-risk, high-reward investment opportunity within the volatile hemp-derived products market. The company's negative profit margin of -402.2% and gross margin of -100.0% indicate significant challenges in achieving profitability. Growth catalysts include expansion into new product lines and increased market penetration within the cosmetic and pharmaceutical sectors. However, the company's OTC listing and high beta of 4.32 reflect substantial market risk and volatility. The investment thesis hinges on Exactus's ability to scale production efficiently, navigate regulatory hurdles, and establish a sustainable competitive advantage in a rapidly evolving industry. The company's future success depends on effectively managing costs and capitalizing on the growing demand for hemp-derived products.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Negative Profit Margin of -402.2% indicates significant challenges in achieving profitability.
- Negative Gross Margin of -100.0% suggests high production costs relative to revenue.
- Beta of 4.32 indicates high volatility compared to the overall market.
- Operates in the rapidly evolving and highly competitive hemp-derived products market.
- Subsidiary of Ceed2Med, LLC, providing a degree of financial backing and operational support.
Wettbewerber & Vergleichsunternehmen
Staerken
- Specialized in hemp-derived ingredients and feminized hemp genetics.
- Offers a range of cannabinoid products including CBD, CBG, CBN, and CBC isolates.
- Provides white-label manufacturing services.
- Serves diverse industries including cosmetic, wellness, and pharmaceutical.
Schwaechen
- Negative profit margin and gross margin.
- High beta indicating high volatility.
- OTC listing reflects higher risk and lower liquidity.
- Dependence on evolving regulatory landscape.
Katalysatoren
- Upcoming: Potential regulatory changes in the hemp-derived products market could create new opportunities or challenges.
- Ongoing: Increasing consumer demand for CBD and other cannabinoid-infused products.
- Ongoing: Expansion of white-label manufacturing capabilities to attract new customers.
- Upcoming: Potential partnerships with established cosmetic or pharmaceutical brands.
- Ongoing: Development of new and innovative cannabinoid formulations.
Risiken
- Ongoing: Intense competition in the hemp-derived products market.
- Potential: Regulatory uncertainty and compliance challenges.
- Potential: Fluctuations in commodity prices for hemp-derived ingredients.
- Potential: Changes in consumer preferences and market trends.
- Ongoing: Negative profit margin and gross margin indicating financial instability.
Wachstumschancen
- Expansion into New Product Lines: Exactus can capitalize on the growing demand for specialized cannabinoid products by expanding its product line to include novel formulations and delivery methods. This includes developing advanced skincare products, pharmaceutical-grade cannabinoid formulations, and innovative wellness products. The market for specialized cannabinoid products is projected to reach $5 billion by 2028, offering a significant growth opportunity for Exactus if they can innovate and capture market share.
- Increased Market Penetration in Cosmetic Sector: The cosmetic industry represents a significant growth opportunity for Exactus, with increasing demand for CBD and other cannabinoid-infused skincare and beauty products. By forging partnerships with established cosmetic brands and developing proprietary formulations, Exactus can expand its market presence in this sector. The global CBD skincare market is expected to reach $3.48 billion by 2029, presenting a substantial opportunity for Exactus to increase revenue and market share.
- Strategic Partnerships with Pharmaceutical Companies: Exactus can pursue strategic partnerships with pharmaceutical companies to develop cannabinoid-based therapeutics and pharmaceutical products. This includes collaborating on research and development efforts, supplying high-quality cannabinoid ingredients, and co-marketing pharmaceutical products. The pharmaceutical cannabinoid market is projected to grow to $2.8 billion by 2028, offering a lucrative opportunity for Exactus to diversify its revenue streams and establish a presence in the pharmaceutical sector.
- White-Label Product Expansion: Exactus can further expand its white-label product offerings to cater to the growing demand from brands seeking to enter the cannabinoid market without investing in their own production facilities. This includes offering a comprehensive suite of white-label products, such as tinctures, capsules, topicals, and edibles, with customizable formulations and branding options. The white-label cannabinoid market is expected to reach $1.5 billion by 2027, providing a significant growth opportunity for Exactus to increase its customer base and revenue.
- International Market Expansion: Exactus can explore opportunities to expand its operations into international markets, particularly in Europe and Asia, where the demand for CBD and other cannabinoid products is growing rapidly. This includes establishing distribution partnerships, setting up local production facilities, and adapting its product offerings to meet the specific regulatory requirements and consumer preferences of each market. The international cannabinoid market is projected to reach $18 billion by 2028, offering a substantial growth opportunity for Exactus to diversify its revenue streams and expand its global footprint.
Chancen
- Expansion into new product lines and markets.
- Strategic partnerships with established brands.
- Increased demand for cannabinoid-infused products.
- Growth in the cosmetic and pharmaceutical sectors.
Risiken
- Intense competition in the hemp-derived products market.
- Regulatory uncertainty and compliance challenges.
- Fluctuations in commodity prices.
- Potential changes in consumer preferences.
Wettbewerbsvorteile
- Proprietary feminized hemp genetics for high cannabinoid yields.
- Established relationships with ingredient suppliers and manufacturers.
- Expertise in cannabinoid extraction and formulation.
- White-label manufacturing capabilities offering customized product solutions.
Ueber EXDI
Exactus, Inc., based in Delray Beach, Florida, specializes in the production and supply of hemp-derived ingredients and feminized hemp genetics. As a subsidiary of Ceed2Med, LLC, the company focuses on providing cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products. These products cater to a diverse range of industries, including cosmetic, wellness, food, beverage, pharmaceutical, and pet sectors. Exactus offers a comprehensive suite of specialty ingredients, including CBD, CBG, CBN, and CBC isolates, as well as CBD and CBG distillates. The company also provides CBD water-soluble solutions, CBD and CBG biomass, CBD and CBG flowers, and CBD crude oil. In addition to these ingredients, Exactus offers custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, and supplements. The company's business model is centered around supplying high-quality hemp-derived products to businesses that incorporate these ingredients into their own consumer offerings. By focusing on both raw materials and finished white-label products, Exactus aims to serve a wide spectrum of needs within the cannabinoid market. The company operates within a rapidly evolving regulatory landscape, requiring constant adaptation to compliance standards and market demands.
Was das Unternehmen tut
- Produces and supplies hemp-derived ingredients.
- Offers feminized hemp genetics.
- Provides cannabidiol (CBD) feminized genetics.
- Supplies high cannabigerol (CBG) feminized genetics.
- Offers hemp-derived specialty ingredients like CBD, CBG, CBN, and CBC isolates.
- Provides white-label products to various industries including cosmetic, wellness, and pharmaceutical.
Geschaeftsmodell
- Sells hemp-derived ingredients to cosmetic, wellness, and pharmaceutical companies.
- Offers feminized hemp genetics to growers.
- Provides white-label manufacturing services for cannabinoid products.
- Generates revenue through the sale of specialty cannabinoid ingredients and finished products.
Branchenkontext
Exactus, Inc. operates within the rapidly expanding, yet highly competitive, hemp-derived products market. This market includes CBD, CBG, and other cannabinoid-based products, catering to the cosmetic, wellness, and pharmaceutical industries. The industry is characterized by evolving regulations, increasing consumer demand, and a fragmented competitive landscape. Companies like Acreage Holdings (ACRDF), and Columbia Care (CLSH) also compete in this space, focusing on various aspects of cannabis and hemp production. The market is projected to continue growing, driven by increasing acceptance of cannabinoid products and ongoing research into their potential health benefits. However, regulatory uncertainty and intense competition pose significant challenges for companies like Exactus.
Wichtige Kunden
- Cosmetic companies using CBD and other cannabinoids in skincare products.
- Wellness companies incorporating hemp-derived ingredients into health and wellness products.
- Pharmaceutical companies developing cannabinoid-based therapeutics.
- Food and beverage companies adding CBD to their products.
- Pet product companies creating CBD-infused pet products.
Finanzdaten
Chart & Info
Exactus, Inc. (EXDI) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer EXDI verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer EXDI.
Kursziele
Wall-Street-Kurszielanalyse fuer EXDI.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von EXDI auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Alvaro Daniel Alberttis
CEO
Alvaro Daniel Alberttis serves as the CEO of Exactus, Inc. His background includes experience in the pharmaceutical and healthcare industries, with a focus on product development and market strategy. He has held various leadership positions in companies focused on developing and commercializing innovative healthcare solutions. Alberttis has a strong understanding of regulatory requirements and market dynamics within the pharmaceutical and cannabinoid sectors. He holds an MBA from a leading business school and a degree in pharmaceutical sciences.
Erfolgsbilanz: Since assuming the role of CEO, Alberttis has focused on expanding Exactus's product offerings and establishing strategic partnerships. He has overseen the development of new cannabinoid formulations and the expansion of the company's white-label manufacturing capabilities. Alberttis has also worked to navigate the evolving regulatory landscape and ensure compliance with industry standards. His leadership has been focused on driving revenue growth and improving operational efficiency.
EXDI OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Exactus, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial reports. Investing in companies on the OTC Other tier involves a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to the lack of regulatory oversight and transparency.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for low trading volume and price volatility.
- Increased risk of fraud or manipulation.
- Difficulty in obtaining reliable financial information.
- Higher risk of delisting or trading suspension.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the regulatory environment and compliance requirements.
- Assess the liquidity and trading volume of the stock.
- Consult with a qualified financial advisor.
- Company is a subsidiary of Ceed2Med, LLC, suggesting some level of oversight.
- Operates in the legitimate hemp-derived products market.
- Offers a range of products and services to various industries.
- CEO has experience in the pharmaceutical and healthcare sectors.
EXDI Healthcare Aktien-FAQ
What are the key factors to evaluate for EXDI?
Evaluating EXDI involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Specialized in hemp-derived ingredients and feminized hemp genetics.. Primary risk to monitor: Ongoing: Intense competition in the hemp-derived products market.. This is not financial advice.
How frequently does EXDI data refresh on this page?
EXDI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EXDI's recent stock price performance?
Recent price movement in Exactus, Inc. (EXDI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized in hemp-derived ingredients and feminized hemp genetics.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EXDI overvalued or undervalued right now?
Determining whether Exactus, Inc. (EXDI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EXDI?
Before investing in Exactus, Inc. (EXDI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding EXDI to a portfolio?
Potential reasons to consider Exactus, Inc. (EXDI) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialized in hemp-derived ingredients and feminized hemp genetics.. Additionally: Offers a range of cannabinoid products including CBD, CBG, CBN, and CBC isolates.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of EXDI?
Yes, most major brokerages offer fractional shares of Exactus, Inc. (EXDI) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track EXDI's earnings and financial reports?
Exactus, Inc. (EXDI) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for EXDI earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is limited and may not be fully up-to-date.
- OTC market investments carry higher risk than exchange-listed stocks.
- The hemp-derived products market is subject to regulatory changes.